Intravenous landiolol, a novel β(1)-adrenergic blocker, reduces the minimum alveolar concentration of sevoflurane in women

• Published in: Journal of clinical anesthesia 2011-06, Vol.23 (4), p.292-296
• Main Authors: Wajima, Zen'ichiro, Tsuchida, Hideaki, Shiga, Toshiya, Imanaga, Kazuyuki, Inoue, Tetsuo
• Format: Article
• Language: English
• Subjects: Adrenergic beta-1 Receptor Antagonists - pharmacology; Adult; Anesthetics, Inhalation - pharmacokinetics; Elective Surgical Procedures - methods; Female; Hospitals, University; Humans; Methyl Ethers - pharmacokinetics; Middle Aged; Morpholines - pharmacology; Prospective Studies; Pulmonary Alveoli - metabolism; Single-Blind Method; Urea - analogs & derivatives; Urea - pharmacology; Young Adult
• ISSN: 1873-4529
• DOI: 10.1016/j.jclinane.2010.11.001

To investigate the effect of intravenous (IV) landiolol, a novel β(1)-adrenergic blocker, on the minimum alveolar concentration (MAC) of sevoflurane in adult women. Prospective, randomized study. University hospital. 42 ASA physical status 1 and 2 women, aged 24-57 years, who were scheduled to undergo elective abdominal surgery. Anesthesia was induced in all patients by vital capacity rapid inhalation induction of sevoflurane. In the landiolol group, administration of landiolol began when patients took a vital-capacity breath: 0.125 mg/kg/min for one minute and then 0.04 mg/kg/min. Normal saline was administered in the control group. MAC was determined by a technique adapted from the conventional up-down method. The MAC of sevoflurane was 2.2% ± 0.2% in the control group and 1.7% ± 0.2% in the landiolol group, a statistically significant difference (P = 0.0005). IV landiolol reduces the MAC of sevoflurane in women by approximately 20%.